Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and Docetaxel in Platinum Refractory or Ineligible Metastatic Urothelial Cancer
NCT03575013Phase 1Completed
- Start
- Oct 2018
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avelumab in urothelial carcinoma (UC). Primary endpoints: Dose Limiting Toxicities up to 5 years and Overall Response Rate up to 5 years. Started Oct 2018; status: completed.
02
Drugs
avelumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03575013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575013.